Gilead’s HIV Treatment Exclusions Send Stock to 192nd in Daily Volume Rankings

On August 25, 2025, Gilead Sciences (GILD) closed with a 0.54% decline, trading at a daily volume of $0.43 billion, a 31.94% drop from the previous day’s activity. The stock ranked 192nd in trading volume among listed equities. The move followed developments in the company’s HIV drug pipeline and coverage decisions by key pharmacy networks.

Gilead, a biopharmaceutical leader specializing in HIV/AIDS, viral hepatitis, and oncology therapies, faces evolving market dynamics. Recent challenges include setbacks in the commercialization of its 99.9% effective HIV prevention shot, which has yet to secure widespread coverage. Pharmacy benefit managers, including a major player, have excluded the new treatment from their drug lists, raising questions about market access and adoption rates. This exclusion underscores broader industry tensions around pricing and reimbursement for innovative therapies.

The company’s collaboration ecosystem remains a strategic pillar, with ongoing partnerships across biotech firms and global pharmaceutical entities. These alliances focus on advancing dual-antigen targeting antibodies, small-molecule therapies, and oral antiviral programs. However, regulatory and commercial hurdles persist, particularly in securing payer support for high-cost innovations in a competitive therapeutic landscape.

A backtested trading strategy involving the top 500 stocks by daily volume yielded a total profit of $2,940 from December 2021 to August 2025. The approach recorded a maximum drawdown of $1,960 and a Sharpe ratio of 1.53, reflecting moderate risk-adjusted returns. The best monthly performance occurred in December 2021 ($840 gain), while August 2025 marked the worst result ($320 loss).